The 'banned overnight' myth: what actually happened to peptides in 2023
The story most patients heard was about a sudden FDA ban. The real story is slower, more procedural — and more useful.
TL;DR
- No peptide was "banned overnight." Several were moved to FDA Category 2 through a multi-year public process.
- Category 2 status means a 503A compounding pharmacy generally cannot prepare that substance — not that the molecule was outlawed.
- FDA removed 12 peptides from Category 2 on April 22, 2026. FDA's advisory committee reviewed seven of them in July 2026. As of September 14, 2026, FDA has not made a final decision.
What it is
The 2023 shift was a Pharmacy Compounding Advisory Committee (PCAC) review that reclassified several peptides as Category 2 substances under the FDA's 503A bulk substances framework (FDA 503A Bulks List). Category 2 is the FDA's holding category for substances with identified concerns. While a substance sits in Category 2, 503A compounding pharmacies generally cannot compound it for patient-specific prescriptions.
How it works
Think of the 503A bulks list as a building permit office. Substances pass through PCAC review and end up in one of three places: Category 1 (under evaluation), Category 2 (significant safety risks identified, on hold), or Category 3 (nominated without adequate support). The 2023 changes did not outlaw any molecule. They moved several peptides into the "on hold" file at once — and that is the moment clinics felt the shelves go bare.
Who asks about it
People come to this topic after reading that peptides were "banned overnight" and trying to square that story with the fact that PCAC meeting agendas were public for years before. The disconnect is between procedural reality and patient experience. Both are true.
What the research says
PCAC meeting transcripts and FDA Federal Register notices show the Category 2 designations followed multi-year reviews (Federal Register, FDA). The substances affected included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II. FDA removed Selank from Category 2 on September 27, 2024. FDA removed the other eight on April 22, 2026, after their nominations were withdrawn. About 9 of the 10 most-asked-about peptides in patient forums ended up in Category 2 or under review. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
What to know before considering it
Patients should not infer current availability from a 2023 headline. The category list shifts. What was unavailable then may or may not be available now, and what is available now can shift again. FDA's published category list — not a press release — is the source of truth.
The Halftime POV
The "banned overnight" framing makes for a clean podcast quote. It is also incorrect, and it sets patients up to be confused when the rules shift again. We will report the date of FDA's formal action — not the date of the headline.
Related reading:
- BPC-157 availability in 2026: where things actually stand
- The three-category peptide access model, explained
- How to choose a quality peptide compounding pharmacy: the quality signals
FAQ
Q: Were peptides "banned overnight" in 2023? A: No. The FDA reclassified several peptides as Category 2 substances through a multi-year, public Pharmacy Compounding Advisory Committee (PCAC) process. The change was procedural and well-telegraphed, even though many patients and clinics experienced it as sudden.
Q: What is Category 2? A: Category 2 is the FDA's holding category for substances that the agency has identified safety or evidence concerns about for use in 503A compounding. While a substance sits in Category 2, 503A pharmacies generally cannot compound it.
Q: Which peptides were affected? A: The Category 2 list has included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II, among others. FDA removed Selank from Category 2 on September 27, 2024. FDA removed the other eight on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, none of them is in any FDA 503A category or on the 503A bulks list. Of the peptides FDA added to Category 2 in 2023, only ibutamoren (MK-677) and kisspeptin-10 remain there. Status can shift as PCAC reviews continue.
Q: Are any of them back? A: In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn. None of them is on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Disclaimer
Several peptides discussed in this article — including KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II — were previously in FDA's Category 2. FDA removed them from Category 2 (September 2024 or April 2026, depending on the peptide). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Were peptides 'banned overnight' in 2023?
No. The FDA reclassified several peptides as Category 2 substances through a multi-year, public Pharmacy Compounding Advisory Committee (PCAC) process. The change was procedural and well-telegraphed, even though many patients and clinics experienced it as sudden.
What is Category 2?
Category 2 is the FDA's holding category for substances that the agency has identified safety or evidence concerns about for use in 503A compounding. While a substance sits in Category 2, 503A pharmacies generally cannot compound it.
Which peptides were affected?
The Category 2 list has included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and Melanotan II, among others. FDA removed Selank from Category 2 on September 27, 2024. FDA removed the other eight on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, none of them is in any FDA 503A category or on the 503A bulks list. Of the peptides FDA added to Category 2 in 2023, only ibutamoren (MK-677) and kisspeptin-10 remain there. Status can shift as PCAC reviews continue.
Are any of them back?
In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn. None of them is on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.